● Recruiting

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Condition: Tumor, Solid · Pancreatic Cancer · Melanoma · Sponsor: UNC Lineberger Comprehensive Cancer Center

PhasePhase 1

Planned participants45

Who can joinAll sexes, 18 Years to 99 Years

Healthy volunteersNo

About this study

This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.

This description comes directly from the study's public registry record.

Talk to the study team

Brian Burgess · 919-966-4432 · brian_burgess@med.unc.edu

Catherine Griffin · 919-966-4432 · catherine_griffin@med.unc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03454035